Results 251 to 260 of about 2,860,326 (352)

Nipah Virus Antibodies in Bats, the Philippines, 2013-2022. [PDF]

Emerg Infect Dis
Kaku Y, Watanabe S, Masangkay JS, Alviola P, Taniguchi S, Cosico E, Une Y, Recuenco FC, Sugimoto S, Kato K, Kyuwa S, General DEM, Manalad AJF, Yap SA, Bando H, Isobe N, Sakata Y, Takeguchi S, Fujii H, Shimojima M, Morikawa S, Maeda K, Omatsu T.   +22 more
europepmc   +1 more source

Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques [PDF]

, 2017
Diamond, Michael S, et al,, Fox, Julie M, Sukulpovi-Petty, Soila   +3 more
core   +1 more source

A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy

Advanced Materials, EarlyView.
A reprogrammed (RP) phage‐based nanovaccine platform has been developed that allows single‐step assembly with precise control over adjuvanticity, antigen density, and nanoparticle size. By enhancing TLR9 activation and neoantigen display, this platform enables a potent personalized vaccine targeting tumor‐specific neoantigens. When combined with immune
Shengnan Huang, Yanpu He, Allison Madow, Huaiyao Peng, Mirielle Griffin, Jifa Qi, Mantao Huang, Heather Amoroso, Riley Abrashoff, Nimrod Heldman, Angela M. Belcher   +10 more
wiley   +1 more source

Antigenic and mutational insights into the Nipah virus G glycoprotein: implications for viral entry, host specificity, therapeutics, and vaccine development. [PDF]

PeerJ
Mohamad Nasir NS, Ismadi YKM, Semail N, Wan Alias WAS, Nik Zuraina NMN, Yusof NY, Deris ZZ, Salleh MZ.   +7 more
europepmc   +1 more source

Spatially Controlled 3‐D Multiplexed Aptamer Patterning in Hydrogels

Advanced Materials Interfaces, EarlyView.
A hydrogel platform based on norbornene‐functionalized polyvinyl alcohol enables high‐resolution, 3‐D multiplexed patterning of DNA aptamers via two‐photon polymerization. Two distinct aptamers are covalently immobilized with single micron‐scale precision across the x, y, and z dimensions.
Kevin Roost, Annina Stuber, Kongchang Wei, Marine de Lapeyrière, Ke Yang, Valentin Gantenbein, Salvador Pané, Ivan Corbeski, Katharina Maniura‐Weber, Nako Nakatsuka   +9 more
wiley   +1 more source

The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection? [PDF]

PLoS Pathog
Na L, Zheng Y, Yang JB, Bao HL, Tang YD.
europepmc   +1 more source

Electrical Monitoring of Vibrio vulnificus–Host Cell Membrane Interactions in Simple and Complex Matrices

Advanced Materials Interfaces, EarlyView.
Supported lipid bilayers coupled with multielectrode array devices offer significant promise for pathogen–host cell membrane interaction studies. This work demonstrates, for the first time, the compatibility of this platform with biological fluids, in this case whole human blood, essential for any future point‐of‐care applications; as well as its ...
Alexandra Wheeler, Zixuan Lu, Jeremy Treiber, Alberto Salleo, Róisín M. Owens   +4 more
wiley   +1 more source

Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates. [PDF]

Nat Commun
Zhu L, Pan S, Huang B, Zhang J, Yang Z, Cong Z, Ma J, Qiu S, Liu Y, Zhang J, Li N, Lu J, Chen T, Hou Y, Zhang D, Wei Q, Li D, Tan W, Zhang Y, Xue J.   +19 more
europepmc   +1 more source

Implantable Microarray Patch: Engineering at the Nano and Macro Scale for Sustained Therapeutic Release via Synthetic Biodegradable Polymers

Advanced Materials Technologies, Volume 10, Issue 6, March 18, 2025.
This review focuses on the application of synthetic biodegradable microarray patches (MAPs) in sustained drug delivery. Compared to conventional MAPs which release drugs into the skin in an immediate manner, these implantable MAPs release drugs into skin microcirculation gradually as the biodegradable polymers degrade, thus offering sustained release ...
Li Zhao, Akmal Hidayat Bin Sabri, Mary B. McGuckin, Linlin Li, Zihao Wang, Eneko Larrañeta, Ryan F. Donnelly   +6 more
wiley   +1 more source

Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial. [PDF]

Cell Discov
Wu Y, Li Y, Zhang P, Guo S, Yuan F, Liu V, Yu T, Lin F, Yang N, Tu C, Lu H, Ying T, Li X.   +12 more
europepmc   +1 more source